Why Johnson & Johnson is staking $785m on Sail’s in vivo CAR-T platform before human trials
Johnson & Johnson backs Sail Biomedicines’ in vivo CAR-T platform with $785 million in initial payments and a $2.58 billion buyout option.
Pharma & Biotech
Pharma & Biotech
Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.